One‐year cardiovascular outcomes of drug‐eluting stent versus bare‐metal stent implanted in diabetic patients with acute coronary syndrome. Issue 5 (May 2016)

• Record Type: Journal Article
• Authors: Lai, Chi‐Cheng; Lin, Tsung‐Hsien; Yip, Hon‐Kan; Liu, Chun‐Peng; Li, Ai‐Hsien; Shyu, Kou‐Gi; Chang, Shu‐Chen; Mar, Guang‐Yuan
• Is Part Of: Journal of the Chinese Medical Association. Volume 79:Issue 5(2016)
• Publication Date: 2016-05
• Subjects: acute coronary syndrome -- bare‐metal stent -- diabetes mellitus -- drug‐eluting stent -- outcome -- percutaneous coronary intervention; Medicine -- Periodicals; 610.5
• DOI: 10.1016/j.jcma.2015.09.004
• Languages: English
• ISSNs: 1726-4901

Abstract

Abstract : Background : The outcomes of drug‐eluting stent (DES) versus bare‐metal stent (BMS) use in patients with diabetic mellitus (DM) and acute coronary syndrome (ACS) are rarely reported in Taiwan. This study aimed to investigate the 1‐year cardiovascular outcomes of DESs versus BMSs implanted in Taiwanese patients with DM and ACS. Methods : For this study, we collected and analyzed patient information from the database of the Taiwan ACS Full Spectrum registry regarding characteristics and cardiovascular events in participants with DM and ACS who received implantation of either BMS (BMS group) or DES (DES group) from October 2008 to January 2010. Results : We found that several characteristics significantly varied between the groups. Compared with the BMS group ( n = 575), the DES group ( n = 199) had significantly lower rates of in‐hospital cardiogenic shock (1.5% vs. 4.9%, p = 0.037) and acute renal failure (0.5% vs. 4.5%, p = 0.008), all‐cause mortality (5.0% vs. 8.9%, p = 0.048), and major adverse cardiac events (MACEs) at 1 year (11.1% vs. 18.6%, p = 0.006) with an identical target vessel revascularization (TVR) rate (6.0% vs. 7.3%, p = 0.395). The BMS group had significantly higher risk‐adjusted all‐cause mortality [hazard ratio (HR) = 2.4, 95% confidence interval (CI) 1.0–5.7; p = 0.048] and MACE (HR = 2.2, 95% CI 1.2–3.9; p = 0.011) at 1 year with identical risks of TVR (HR = 1.3, 95% CI 0.6–2.9; p = 0.505) and nonfatal myocardial infarction (HR = 1.5, 95% CI 0.5–4.4; p = 0.478). Conclusion : The results of this study support the use of DES over BMS in Taiwanese patients with DM and ACS, providing the clinical benefits of lower rates of total mortality and MACE, and without increased TVR at 1 year in a real‐world setting.